Last reviewed · How we verify
Suprasensory
Suprasensory is a Small molecule drug developed by University of Aarhus. It is currently in Phase 1 development. Also known as: Device: External pacemaker, model 3625, Medtronic Inc..
Suprasensory electrical stimulation (ESS) has been studied as a treatment for various conditions, including stroke, neurogenic bowel, spinal cord injuries, and irritable bowel syndrome. The method involves delivering electrical stimulation above the sensory threshold, and it has been tested in both continuous and intermittent forms, as well as in combination with transcutaneous spinal cord stimulation.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Suprasensory |
|---|---|
| Also known as | Device: External pacemaker, model 3625, Medtronic Inc. |
| Sponsor | University of Aarhus |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Transcutaneous Spinal Cord Stimulation for Bowel Management in Individuals with Motor Complete Spinal Cord Injury (NA)
- Subsensory Sacral Nerve Stimulation for Irritable Bowel Syndrome (NA)
- Electrical Stimulation of the Paretic Upper Limb in the Early Stroke Phase (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Suprasensory CI brief — competitive landscape report
- Suprasensory updates RSS · CI watch RSS
- University of Aarhus portfolio CI
Frequently asked questions about Suprasensory
What is Suprasensory?
Who makes Suprasensory?
Is Suprasensory also known as anything else?
What development phase is Suprasensory in?
Related
- Manufacturer: University of Aarhus — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Device: External pacemaker, model 3625, Medtronic Inc.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing